Pharmacoeconomic Analysis of Three Therapeutic Schemes for Chronic Hepatitis B
- VernacularTitle:3种方案治疗慢性乙型肝炎的经济学分析
- Author:
Yaming DU
- Publication Type:Journal Article
- Keywords:
IFN?-2b;
Lamivudine;
Chronic hepatitis B;
Cost-effectiveness analysis
- From:
China Pharmacy
2007;0(29):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To evaluate the economic effects of three therapeutic schemes for chronic hepatitis B.METHODS:116 patients with chronic hepatitis B were divided into 3 groups:Group A(n=38) received lamivudine(100 mg?d-1,po) for 6 months;Group B(n=38) received IFN?-2b(3million IU?d-1,im) for 4 weeks followed by IFN?-2b(im,3million IU,qod);Group C(n=40) received IFN?-2b(3million IU?d-1,im) for 4 weeks followed by IFN?-2b(im,3million IU,qod) plus lamivudine(po,100 mg?d-1).The course of treatment for the three groups all lasted for 6 months.The cost-effectiveness of the three groups was evaluated using the principle of pharmacoeconomics.RESULTS:In A,B,and C groups,the costs were 3 420,12 168 and 15 588 Yuan,respectively,and the HBV-DNA negative changing rates were 44.7%,47.4% and 67.5%,respectively.The increment in cost for one more unit of effectiveness was 324 000.00 Yuan in Group B and 53 368.42 Yuan in Group C as compared with Group A.CONCLUSION:Scheme C is the optimal one pharmacoeconoically.
